These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37589096)

  • 1. Baclofen and Tizanidine Adverse Effects Observed Among Community-Dwelling Adults Above the Age of 50 Years: A Systematic Review.
    Killam-Worrall L; Brand R; Castro JR; Patel DS; Huynh K; Lindley B; Torres BP
    Ann Pharmacother; 2024 May; 58(5):523-532. PubMed ID: 37589096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baclofen and the risk of fall and fracture in older adults: A real-world cohort study.
    Hwang YJ; Chang AR; Brotman DJ; Inker LA; Grams ME; Shin JI
    J Am Geriatr Soc; 2024 Jan; 72(1):91-101. PubMed ID: 37933734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of baclofen versus tizanidine for older adults with musculoskeletal pain.
    Su Zhang VR; Niu F; Lee EA; DiStasio C; Broder BI; Steinberg SG; Hui RL
    J Am Geriatr Soc; 2023 Aug; 71(8):2579-2584. PubMed ID: 36989193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS).
    Villa-Zapata L; Gómez-Lumbreras A; Horn J; Tan MS; Boyce RD; Malone DC
    Drug Saf; 2022 Aug; 45(8):863-871. PubMed ID: 35834155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Efficacy and Side Effects of Oral Baclofen Versus Tizanidine Therapy with Adjuvant Botulinum Toxin Type A in Children With Cerebral Palsy and Spastic Equinus Foot Deformity.
    Dai AI; Aksoy SN; Demiryürek AT
    J Child Neurol; 2016 Feb; 31(2):184-9. PubMed ID: 25999301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis.
    Eyssette M; Rohmer F; Serratrice G; Warter JM; Boisson D
    Curr Med Res Opin; 1988; 10(10):699-708. PubMed ID: 3286128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin type A with oral baclofen versus oral tizanidine: a nonrandomized pilot comparison in patients with cerebral palsy and spastic equinus foot deformity.
    Dai AI; Wasay M; Awan S
    J Child Neurol; 2008 Dec; 23(12):1464-6. PubMed ID: 19073853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of delirium, motor disturbances, and autonomic dysfunction due to baclofen and tizanidine withdrawal: a review of the literature.
    Karol DE; Muzyk AJ; Preud'homme XA
    Gen Hosp Psychiatry; 2011; 33(1):84.e1-2. PubMed ID: 21353141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An approach to switching patients from baclofen to tizanidine.
    Brenner R; Hyman N; Knobler R; O'Brien M; Stephan T
    Hosp Med; 1998 Oct; 59(10):778-82. PubMed ID: 9850294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological interventions for spasticity following spinal cord injury: results of a Cochrane systematic review.
    Taricco M; Pagliacci MC; Telaro E; Adone R
    Eura Medicophys; 2006 Mar; 42(1):5-15. PubMed ID: 16565680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.
    Smolenski C; Muff S; Smolenski-Kautz S
    Curr Med Res Opin; 1981; 7(6):374-83. PubMed ID: 7016449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baclofen and the Risk of Encephalopathy: A Real-World, Active-Comparator Cohort Study.
    Hwang YJ; Chang AR; Brotman DJ; Inker LA; Grams ME; Shin JI
    Mayo Clin Proc; 2023 May; 98(5):676-688. PubMed ID: 37028980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pediatric safety of tizanidine: clinical adverse event database and retrospective chart assessment.
    Henney HR; Chez M
    Paediatr Drugs; 2009; 11(6):397-406. PubMed ID: 19877725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative profile of tizanidine in the management of spasticity.
    Lataste X; Emre M; Davis C; Groves L
    Neurology; 1994 Nov; 44(11 Suppl 9):S53-9. PubMed ID: 7970011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence associated with oral medications in the treatment of spasticity.
    Halpern R; Gillard P; Graham GD; Varon SF; Zorowitz RD
    PM R; 2013 Sep; 5(9):747-56. PubMed ID: 23648652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients.
    Henney HR; Runyan JD
    Int J Clin Pract; 2008 Feb; 62(2):314-24. PubMed ID: 18199279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects.
    Henney HR; Shah J
    Clin Ther; 2007 Apr; 29(4):661-9. PubMed ID: 17617289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A controlled pharmacokinetic evaluation of tizanidine and baclofen at steady state.
    Shellenberger MK; Groves L; Shah J; Novack GD
    Drug Metab Dispos; 1999 Feb; 27(2):201-4. PubMed ID: 9929503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis.
    Bass B; Weinshenker B; Rice GP; Noseworthy JH; Cameron MG; Hader W; Bouchard S; Ebers GC
    Can J Neurol Sci; 1988 Feb; 15(1):15-9. PubMed ID: 3345456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam.
    Groves L; Shellenberger MK; Davis CS
    Adv Ther; 1998; 15(4):241-51. PubMed ID: 10186943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.